New £30m Initiative to Address Global Threat by Accelerating the Pace of Antimicrobial Innovation!
Pioneering partnership to drive development of new tests and treatments to tackle deadly antimicrobial resistance, which could otherwise kill 10 million a year by 2050
Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced its first funding call with up to £10 million available to support innovators developing new antimicrobials.
As the UK’s largest public-private initiative targeting early-stage antimicrobial drug and diagnostic discovery, PACE will select, invest in and support projects that address the world’s most threatening pathogens. It will deliver innovations for onward development and investment, moving them closer to clinical trials. By tackling this problem collectively, with a pandemic-style focus, the early translational science community will be supported to deliver the breakthroughs needed.
Press release for PACE:
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!